Screener
Ocular Therapeutix OCUL Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest expense | (2,777) | (2,984) |
| Change in fair value of derivative liabilities | 1,455 | (978) |
| Total other income (expense), net | 4,728 | (136) |
| Net loss | $(88,612) | $(64,053) |
| Net loss per share, basic | $(0.40) | $(0.38) |
| Weighted average common shares outstanding, basic | 224,099,410 | 169,396,989 |
| Net loss per share, diluted | $(0.40) | $(0.38) |
| Weighted average common shares outstanding, diluted | 224,099,410 | 169,396,989 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's business segments — net income loss?
- Ocular Therapeutix (OCUL) reported business segments — net income loss of -$88.61M in Q1 2026.
- How has Ocular Therapeutix's business segments — net income loss changed year-over-year?
- Ocular Therapeutix's business segments — net income loss decreased by 38.3% year-over-year, from -$64.05M to -$88.61M.
- What is the long-term trend for Ocular Therapeutix's business segments — net income loss?
- Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — net income loss has grown at a 55.3% compound annual growth rate (CAGR), from -$71.04M to -$265.94M.
- What does business segments — net income loss mean?
- This is the bottom-line financial result for the company's primary business segment, representing total revenues minus all operating and non-operating expenses. It serves as the ultimate measure of the segment's profitability and financial health. For biotechnology firms, this often reflects the balance between heavy investment in clinical pipelines and the revenue generated from commercialized products.
Ask your AI about Ocular Therapeutix's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude